HQL: Attractive Outlook With Growth Of GLP-1 Market (NYSE:HQL)
· seekingalpha.com
Discover why HQL earns a buy rating: 12.6% yield, 8.49% NAV discount, GLP-1 biotech upside, plus key risks for income investors—read now.
When I previously covered the abrdn Life Sciences Investors Fund ( HQL ), I issued a buy rating because of the attractive valuation and healthy NAV growth at th...